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Natural killer cells or NK cells have been known since the
70s on the basis of their functional properties [1, 2], but es-
sentially no molecular markers existed able to speciﬁcally
identify them. Still in the early eighties, the few scientists
that worked in NK cells ﬁeld had diﬃculty convincing about
the existence of those cells while, in the same period, immu-
nologists were essentially in the search of the δ-chain of the
T-cell receptor.
Nowadays, following the molecular characterization of
diﬀerentsurfacereceptorsandthesignallingpathwaysaswell
as the characterization of the molecules speciﬁcally recog-
nized and the analysis of their 3D-structures, the research on
NK cells has become a highly competitive ﬁeld. Researchers
studying diﬀerent functional and molecular aspects have
been challenged to understand the function of these cells and
the mechanism of the regulation of their function in terms
of NK cell licensing or education and NK memory. In ad-
dition, it is always more complex the crosstalk with other
cell of the immune system either by cell contact or through
the release of soluble factors. Brieﬂy, natural killer cells are
responsible for the immune responses against tumor or
virally infected cells. Their function is tightly regulated by a
clonal and stochastic distribution of germline-encoded cell
surface receptors, and these molecules are able to deliver
either inhibitory or activating signals. Thus, every NK cell
is equipped by at least a single inhibitory receptor which is
functionally dominant and that senses the level of surface
expression of MHC class I molecules on autologous cells
mediating self-tolerance [3–15]. This function has been
maintained during mammalian evolution by expansion
of diﬀerent multigene families coding for receptors with
marked structural divergences that have been evolved in the
diﬀerent species together with appropriate MHC molecules
serving as ligand [16]. Any alteration on target cell of the
surface expression level of the MHC class I molecules,
induced by viral infection or tumor transformation, induces
NK-mediated cell killing. NK cell receptors evolved in a
highly dynamic fashion, primarily driven by the necessity
to deal with a large variety of pathogens and to recognize
properties of cells characteristic of tumor transformation.
In this special issue, a series of reviews or articles on
natural killer cells are published and summarize information
related to NK cells and diseases and the rationale use of these
knowledge for clinical applications. In detail we summarize
the molecular and structural analysis of NK receptor and
their interaction with ligands and how the diversity of KIR
genotype and of HLA class I molecules are related with the
outcome of a number of key human infections [17, 18].
Other contributions are based on the analysis of the knowl-
edges regarding the molecular interactions between NK cells
and myeloid antigen-presenting cells and their role in the
regulation/polarization of adaptive immune responses [19,
20]. The ability of distinct species of gut-derived commensal
bacterialtodiﬀerentlyaﬀecttheoutcomeofDC/NKcrosstalk
and the Th1 polarization of the adaptive immune response is
also discussed [19, 20]. The complex network of interactions
involving the immune system is also through the use of cy-
tokines. The functional redundancy and the speciﬁc role of
the common gamma-chain cytokine family (IL-2, IL-4, IL-
7, IL-9, IL-15, and IL-21) in the regulation of the immune
response and in the homeostasis of the lymphoid cells and
the acquisition of memory-like functions have been analyzed
[21]. In addition, novel strategies to deliver cytokines and
the use of immunokine aimed to maximize their therapeutic2 Journal of Biomedicine and Biotechnology
potential and to costimulate the NK cell activation by en-
hancing NK cell adhesion to target cells have been described
[21, 22]. Several reviews analyze the mechanism of recog-
nition used by NK cells to sense viral pathogens, like HCV,
HBV,HIV,CMV,andotherinfectiousdiseases[1,23–25]and
the potential role of NK cells during severe sepsis and septic
shock [26]. Cytomegaloviruses evolved diﬀerent mecha-
nisms to hide and survive to immune-related responses. In-
nate immunity is the ﬁrst line of defence in the case of CMV
infections, and viral particles are known to modulate the
expression of ligand molecules speciﬁc for NK-triggering
receptor on the surface of infected cells. In addition, some
viralgenesarealsoknowntoencodeMHCclassI-likesurface
molecules contributing to immunoevasion both in mice and
in humans [23, 24]. Since CMVs and their respective hosts
coevolved, it is tempting to speculate that the viral MHC
class-I-like molecules originate from the host genomes.
Revillezaetal.onthebasesofnucleotides,proteins,andcrys-
tallographic/modellingstructuraldataobtainedfromhuman
and mice speculate that a single ancient event of partial
genome transfer and not multiple phenomena may have
evolved the diﬀerent CMV class I-like molecules [23]. In
various mice strains the capture of host-genome has origi-
nallyallowedthedevelopmentofMHCclass-I-likemolecules
able to interact with inhibitory Ly49 receptors. Instead B6
and Ma/My have evolved activating Ly49 molecules, which
through the interaction with viral class I-like molecules and/
or with the presence of additional factors are able to trigger
NK cell cytolysis rather than inhibit and probably to con-
tribute to the development of NK cell memory [24]. Thus it
appears clear that there is a strict interplay among NK cells,
their receptors and the responses toward viral pathogens. To
address these issues, we have an depth analysis discussing
the diﬀerent triggering receptors expressed by NK cells, their
level of expression and the possible ligands involved in
the interaction with cells infected by viruses belonging to
diﬀerentfamilies (Orthomyxo-, Paramyxo-,Flavi-, Lentiviri-
dae) [25]. Thanks to the latest review in which we have
found discussed the NK-mediated responses following viral
pathogen infection, here we ﬁnd some recent points of view
about how also microbial sepsis and the “systemic inﬂam-
matory response syndrome” or peptic shock may be related
with NK cell-immune responses [26]. All the information
regarding NK receptors and their ligands, as well as the ﬁne
regulation of innate/acquired immune-responses orches-
trated by NK cells and the cytokines network are the basis for
better use in cancer therapy. The NK cell responses toward
tumor using speciﬁc mAbs and an ADCC mechanism and
all attempts to increase anti-tumor cell cytotoxicity using
cytokine combinations, TLR agonist and immunokines are
also discussed [27, 28]. ADCC is often impaired in PBMC
from patients with advanced cancer as a result of NK cell
dysfunction probably generated by tumor-produced soluble
factor(s) (i.e., TGFβ), thus any approaches aimed to increase
the ADCC killing are necessary to obtain an eﬃcient tumor
cell readication.
Along this line, IL15, IL2 and the use of Lenalidomide,
an analog of thalidomide known to increase FcγR-mediated
signalling, adoptive cell transfer and ex-vivo cell expansion,
have been successfully used [28]. Although, the ﬁrsts at-
tempts in the use of autologous ex vivo expanded cells did
not give encouraging results, it is now clear the basis of these
failures, making allogeneic cell transfer more attractive. The
use of KIR/HLA class I-mismatched cells, selected in order to
be not sensitive to inhibitory signals from the recipient HLA
ligands, have been proved to be protective against disease
relapses [28].
The other face of the coin of NK cells and tumor is
shown by Schmitt et al, that focalizes our attention on a rare
form of hematolymphoid tumors including the extranodal
NK/T-cell lymphoma (NKTCL) that is considered inside the
provisional group of chronic NK-cell lymphoproliferative
disorder. This lymphoma is apparently associated with EBV-
associated malignancy with very poor prognosis, rare in
western countries, but it represents at least 10% of non-
Hodgkin’s lymphomas in Asia and Central/South America
[29]. Finally, two reviews are taking care of using the
combined analysis of genetic data regarding KIR and HLA
class I molecules and their association in autoimmune dis-
eases and the cytokines network below the pathogenesis of
chronic inﬂammation [30, 31]. In both cases, a decrease of
the strong inhibitory pathways controlled by HLA-C-speciﬁc
receptors and thus a reduced activating threshold promote
immune responses, and this eﬀect of changing the threshold
ofimmune-suppression/activationmaycontributetoexplain
the genetic susceptibility of diﬀerent autoimmune diseases.
In the last years, we have assisted to an explosion in the
researchﬁeldcenteredonNKcells.Inthenearfuture,wewill
see the publication of diﬀerent results in the regulation of
receptors and ligands expression by miRNA, as exempliﬁed
by the recent published article regarding the control of HLA-
C expression in HIV infection [32]. There are diﬀerent ar-
guments that need a detailed study. Among these, we also
know that KIR recognizes HLA class I ligands on the basis
of the presence of particular amino acid residues; probably
diﬀerent exceptions exist. In addition, very little information
isavailableabouttheroleofviralpeptides,presentedbyHLA
class I able to trigger the activation of Killer Ig-like Receptors
(KIR2DS, KIR3DS). The absence of such information might
explain the failure, so far, of an experimental identiﬁcation
of ligands speciﬁc for diﬀerent triggering KIR, with a single
exception [33]. Finally, a complete characterization of the
molecules recognized by all the cloned NK cells receptors is
still needed to analyze in detail all the triggering pathways
induced by NK cell-mediated recognition.
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